APBMT Annual Report 2021

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT
Copyright APBMT Annual Report 2021

Worldwide Confidentiality Note: Dissemination, distribution or copying of this document or the information herein by anyone other than the approved recipient is prohibited. If you are not the intended recipient, please inform APBMT Secretariat (office@apbmt.org).

Prior approval must be sought from APBMT before releasing any data from this document publicly, and APBMT must be acknowledged as the data source. The suggested citation is: "APBMT Annual Report 2021".

This document contains information on hematopoietic stem cell transplants and cell therapies provided voluntarily by participating countries/regions in the Asia-Pacific region. The data and its analysis are the property of APBMT. This APBMT resource is intended for use by its members and approved participating clinical and research organizations.

While all care has been taken in the compilation of this document, no responsibility can be taken for misuse of the data or for data errors that have been unintentionally included.
Asia-Pacific Blood and Marrow Transplantation Group (APBMT)

Annual Report 2021

Secretariat Office / Data Center of APBMT

E-mail: office@apbmt.org
Website: https://www.apbmt.org
Contents

Introduction
General Overview 2021
Bylaws
Organizational Tree
Principal Member List

Annual Congresses
Guidelines for the hosting of the APBMT annual congress
Previous and Future Congresses
The Number of Attendees for Each Annual Congress from 2012 to 2021

Registry Committee
About Registry Committee
About Activity Survey
About Outcome Registry
Registry Committee Member List

Nuclear Accident Management (NAM) Committee
NAM Committee Activities and Member List

Executive Board
Executive Board Activities
Executive Board Members

Collaboration with Other International Registries
General Information
History of International Scientific Symposia

Blood Cell Therapy -The Official Journal of APBMT-
About the Journal
Editorial Board Member List
List of the Accepted Articles

Appendix
Cooperate Members and Banner Contributions
Introduction
General Overview 2021

All 22 of APBMT’s participating countries/regions are listed here. (As of December 2021)

Australia
Bangladesh
Cambodia
China
Hong Kong
India
Indonesia
Iran
Japan
Korea
Malaysia
Mongolia
Myanmar
Nepal
New Zealand
Pakistan
Philippines
Singapore
Sri Lanka
Taiwan
Thailand
Vietnam

This Annual Report is the 14th edition overall and the second edition following our transition to this new digital format. It includes APBMT activities from January to December in 2021. Though the COVID-19 pandemic continued to powerfully influence the field of HSCT medicine in this region throughout the year, all doctors and allied health professionals made a great effort to care for patients with hematological diseases.

The 26th annual congress in Thailand was held on the hybrid platform and the organizing committee in Thailand successfully convened it in collaboration with the APBMT Executive Board. APBMT approved new guidelines for the hosting of the annual congress this year, and future annual meetings will be run in accordance with these guidelines.

Please note that, the results of the Activity Survey are separated from the Annual Report from the last edition. You can find them on the APBMT website:
https://www.apbmt.org/research/registry/survey
ARTICLE 1
Name of the Group

The Asia Pacific Blood and Marrow Transplantation Group, hereafter referred to as APBMT was established in 1990 to allow doctors, other health professionals and scientists in the Asia Pacific region involved in clinical blood and marrow transplantation and therapies related to hematopoietic stem cell transplantation to collaborate and promote high quality blood and marrow transplantation in the region.

ARTICLE 2
Incorporation

APBMT is incorporated as Corporate Juridical Person for scientific and educational purposes under the laws of Japan.

ARTICLE 3
Purpose of APBMT

The group aims to promote all aspects associated with the hematopoietic stem cell transplantation (HSCT) and related therapies in the Asia Pacific region, which includes:

- To ascertain and provide the updated status of haematopoietic stem cell transplantation (HSCT) in the Asia Pacific region.
- To steer and regulate the HSCT Registry in the Asia Pacific region (Asia Pacific Blood and Marrow Transplantation Group Registry: APBMT Registry)
- To share current knowledge of all aspects of HSCT to promote and maintain the highest standards of care, and to work towards a set of standards and accreditation of transplant units.
- To provide training opportunities in HSCT in the Asia Pacific region.
- To promote collaborative research in the Asia Pacific region.
- To collaborate with other international organizations related with HSCT
- To work as a core voting member of WBMT
ARTICLE 4

Organization

The schema of the organization in APBMT indicates below.

4. Membership

Any persons involved in the treatment of recipients and donors (such as physicians, nurses, laboratory technicians, persons related to stem cell donor programs or pharmaceutical companies), who are involved in HSCT and agree with the purpose of the group can become a member (see above section). New members are admitted by submitting a membership application form and CV up to 2 pages to the Secretary Office. This application must include the signature of an APBMT member as a presenter. There are two different kinds of memberships; Scientific members (physicians, nurses, laboratory technicians, persons related to stem cell donor programs) and Corporate members (pharmaceutical and for-profit companies). Scientific members include Regular, Associate, Affiliate, Honorary and Emeritus members. All members have to pay annual membership fees except for the Honorary and Emeritus members.

4.1 Regular members
Regular members consist of members from medical fields with an M.D. or Ph.D sufficient experiences and demonstrated in hematopoietic stem cell transplantation / cellular therapy. A proposed new member must provide a membership application form and CV that includes professional qualification, work experiences, current employment and place of work to the Secretariat Office. Regular members must agree to abide by the regulations of APBMT, to participate in scientific endeavors of APBMT, to have good ethical and moral standards as well as no criminal record, as expected by professional societies. Regular members can attend the Business meeting but do not have voting right. Regular members can elect and can be elected as Scientific Committee members within each country.

4.2 Associate members
Individuals with and M.D. or Ph.D who do not meet the criteria for regular membership will become Associate members. Associate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.3 Affiliate members
Professionals who are members of HSCT / cellular therapy team or interested in HSCT / cellular therapy (NP, PA, Pham D, RN etc.) are eligible to be Affiliate members. Affiliate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.4 Emeritus members
Anyone in APBMT who has contributed in a significant way to its development is eligible to become Emeritus Members. Emeritus members are nominated by the Executive Board and are approved by the Scientific Committee at the business meeting. Emeritus Members are eligible to participate in the business meeting.

4.5 Honorary members
Individuals who are not an APBMT member but have contributed to the establishment or the development of APBMT are eligible to become an Honorary member. Honorary members are nominated by the APBMT members and are approved by the Scientific Committee at the business meeting. Honorary
members are ineligible to participate in the Business meeting.

4.6 Corporate members
Representatives of commercial and for-profit companies can become Corporate members. Corporate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.7 Scientific Committee
Scientific Committee is the supreme decision-making body in APBMT. Each country can elect and nominate 1 voting member as the country representative. The vote is casted by the country representative but this right may be transferred to a designated substitute. If there is more than one nominee from one country, the Scientific Committee can vote to select one candidate. The names of the current members of scientific committee are listed and updated annually. The Chairman of the Executive Board, who also serves as the Chairman of the Scientific Committee, has the deciding vote if the vote is otherwise tied.

New Scientific Committee members need to be recommended by the current members of Scientific Committee among the members of the Regular Members and to get approval in the business meeting. Decisions are taken by majority voting (One vote/one country). A proposed new member must provide a brief CV up to 3 pages. The criteria to be a Scientific Committee Member include proven medical and/or scientific experience in HSCT; willingness to committee and participate in scientific endeavors of APBMT; no criminal record, good ethical and moral standards as expected by professional societies.

The Scientific Committee member has the following rights and obligations: 1) To attend the Annual Business Meeting; 2) To elect Executive Board members; 3) To decide on admission of new members; 4) To decide the annual fee for APBMT membership; 5) To make final decision on APBMT policies and its finance.

A Scientific Committee member will lose his/her rights as a representative of his/her country/region when he/she leaves his/her original country/region permanently.

4.8 Executive Board
The Executive Board of APBMT steers the group for administration and all decisions that need to be taken for functioning of the organization in accordance
with the constitution and bylaws of the organization. The Executive Board is responsible for all running operations and decisions that are not due to be taken by the Scientific Committee at the annual meeting. The Executive Board, appointed by the Scientific Committee, will act on behalf of all members for regular decisions during the period between Scientific Committee meetings. During this period, the Scientific Committee need not be consulted unless a decision would affect the bylaws or contravene a decision previously made by the Scientific Committee. The Executive Board consisted of regular members (only one member permitted from one country) elected from the Scientific Committee. The maximum number of members of the Executive Board is nine. The Chairman of Executive Board represents APBMT.

4.9 Officers of the Executive Board
1. Scientific Committee elects a) one Chairman of Executive Board, b) one Vice Chairman of Executive Board, c) several other Members of Executive Board including one Secretariat / Treasurer. The members of the Executive Board are elected by the business meeting, and serves for two years and may be re-elected for another term of two years.
2. The function of the Chairman of Executive Board is to promote and coordinate all activities of APBMT. These include fund raising, coordination of Working Group activities, giving suggestions to the organizers of the annual meeting, and negotiations with other organizations on behalf of APBMT.
3. The Vice Chairman supports the Chairman and will perform the duties of the Chairman in the absence.

4.10 Secretariat/Treasurer
Secretariat / Treasurer shall oversee the maintenance of a permanent record of APBMT. The Secretariat / Treasurer shall have oversight of the budget of APBMT. The Secretariat / Treasurer Office works for the development and the maintenance of the group under the collaboration with the Chairman of Executive Board, the Chairman of the next annual congress, and the members of Executive Board and Scientific Committee.

ARTICLE 5
Committees and Working Groups
5.1 Committees
APBMT will have the following Standing Committees to help with its work.
1. Membership Committee
2. Registry Committee
3. Program Committee
4. Nuclear Accident Management (NAM) Committee
5. Editorial Board of the Blood Cell Therapy, the Official Journal of APBMT

Each of these committees will have a specific term of reference.

5.2 Working Groups
The aim of Working Groups is to enhance research in focused areas. The Executive Board and Scientific Committee of APBMT determine the formation of Working Groups as required. The application of the new Working Group and its chair person is approved by the members of the Scientific Committee in the Business Meeting (see Annex). The chair person of each Working Group is elected for three years and may stand for reelection once. The substructure of the Working Group is defined by the chair person in consultation with the Executive Board. Regular Members are encouraged to participate in one or more Working Groups according to their particular interests. The Working Group chair person must submit annual activity reports to the Scientific Committee and the Executive Board. The chairperson should adhere to the Working Group responsibilities, which are specified separately from the bylaws.

ARTICLE 6
Meetings
6.1 Annual Congress
Any countries participating in APBMT can propose to be a host country of the Annual Congress. Host country of the future Annual Congresses will be decided by the Scientific Committee. The President of the next annual congress cooperates with the Executive Board for the year preceding the annual congress. The format of the meeting is to be standardized (see Annex section below).

6.2. Business Meeting
The Scientific Committee will open the Business Meeting at least once a year. One of them will be held during the annual meeting. It is co-chaired by the Chairman of the Executive Board and the President of the Annual Congress. The Board may establish subcommittee / working party as the need arises.
6.3 Board Meeting
The Executive Board of the APBMT shall meet in person at the annual meeting. It is presumed that all members will attend this meeting unless there are unavoidable personal circumstances. In addition, the board will meet via conference calls every 4-8 weeks, as needed. All members are expected to attend all scheduled board meetings.

ARTICLE 7

7.1 APBMT Registry
A major activity of the APBMT will be to guide the development of national registries in each country. This data will then be collected into the combined APBMT registry in formats compatible with other international registries. Both activities and outcome data will be collected every year.

7.2 Annual Report
The list of registrants and summary of analyses are published in the APBMT Annual Report of each year, which is distributed to the APBMT member and related persons / organizations. The results published in the APBMT Annual Report is confidential, however, it can be quoted after written approval from APBMT and accompanied by proper acknowledgement.

7.3 Rules on the use of the Registry data
Data are restricted to publication in a scientific article and / or presentation at academic meetings. APBMT contributions must be appropriately acknowledged in all presentations and publications prior to the release of the data and analyses. Written Applications for these purposes are limited to Scientific Committee Members, Working Groups and the Data Center of APBMT for the time being. Written requests from other academic organizations or commercial companies will be assessed and if approved a cost recovery will be charged depending on the amount of work. Confidentiality of source information will be protected in accordance with the laws of individual centres and countries. An application form is attached as a separate sheet. The Registry Committee will evaluate all applications and approval made after consultation with the Executive Board.

ARTICLE 8
Finance

8.1 Membership Fees:
All the Regular Members are required to pay annual membership fees on an individual basis (see Annex). The members who paid the membership fees can receive up-to-date information including the survey data from APBMT office and also may have the advantage of discount of the registration fees at annual congress.

8.2 Statement of accounts of annual APBMT congress
An audited statement of accounts must be prepared by the organizing committee for each annual APBMT meeting within one year of its completion and submitted to the APBMT Headquarters and presented at the annual business meeting.

ARTICLE 9
Amendments
9.1 These Bylaws may be amended at any annual business meeting of the Scientific Committee Amendments to the Bylaws may be proposed in writing to the Executive Board and must be submitted at least ninety days prior to the annual meeting. In addition, the Executive Board may initiate proposed amendments to the Bylaws.

The proposed amendments, together with the Executive Board’s recommendation, shall be distributed to members of the Scientific Committee at least thirty days before the annual meeting at which it is to be considered. To be adopted, an amendment must be approved by at least two thirds of voting at the annual meeting.

9.2 Annexures may be amended by the Executive Board, (with a minimum of two third majorities of the members of the Executive Board) and report to the Scientific Committee.

Annexures:
1. Committees - Terms of Reference to be determined.
2. Working Groups - Terms of Reference to be determined.
3. Annual Congress – Format of the meeting to be formulated
4. The APBMT Registry
5. Financial Issues
6. The Scientific Committee members: In addition to the criteria to be a Scientific Committee Member described in APBMT Bylaw (4.7 Scientific Committee), the candidate must have served as a regular member for the past three years with the consecutive payment of annual membership fee. No term limits are set for Scientific Committee Members. However, the members are required to participate in at least 2 out of 4 most recent APBMT Annual Congress, and consecutively pay annual membership fee in order to maintain their membership. In addition, their willingness of serving as Scientific Committee Members is to confirm every two years. No limits are set for the maximum number of Scientific Committee members in each country/region participating APBMT.

7. Others
(Detailed rules such as payments and duties for the members are described in the annexure)

Establishment: October 1, 2009
History of revision:
   December 31, 2010
   October 31, 2015
   November 1, 2016 (Annexure 6 was added.)
   August 31, 2019
Principal Member List

Executive Board members

Shinichiro Okamoto (Chairman, Japan)  Alok Srivastava (Vice-chair, India)  David D Ma (Australia/New Zealand)

He Huang (China)  Amir Ali Hamidieh (Iran)  Jong Wook Lee (Korea)

William YK Hwang (Singapore)

Scientific Committee Members (*Executive Board members *)

Yoshiki Akatsuka (Japan)  Otgonbat Altangerel (Mongolia)  Shashikant Apte (India)

Khishigjargal Batsukh (Mongolia)  Carmella Bingcang (Philippines)  Pheng Bora (Cambodia)

Udomsak Bunworasate (Thailand)  Po-Min Chen (Taiwan)  Tzeon-Jye Chiou (Taiwan)

Sharat Damodar (India)  Gin Gin Gan (Malaysia)  Lallindra Gooneratne (Sri Lanka)

Aye Aye Gyi (Myanmar)  Amir Ali Hamidieh (Iran)  *  Suradej Hongeng (Thailand)

He Huang (China)  *  Xiao-Jun Huang (China)  Tai-ju Hwang (Korea)

William YK Hwang (Singapore)  *  Hyoung Jin Kang (Korea)  Mohiuddin Khan (Bangladesh)

Navin Khattry (India)  Bor-Sheng Ko (Taiwan)  Mickey Koh (Singapore)

Hoon Kook (Korea)  Hsiao Liang-Tsai (Taiwan)  Jong Wook Lee (Korea)  *

Albert Lie (Hong Kong)  Kai-Hsin Lin (Taiwan)  Kai-yan Liu (China)

David D Ma (Australia/New Zealand)  *  Koichi Miyamura (Japan)  Shinichiro Okamoto (Japan)  *

Jian Ouyang (China)  Chi Dung Phu (Vietnam)  Bishesh Sharma Poudyal (Nepal)

Damai Santosa (Indonesia)  Tahir Sultan Shamsi (Pakistan)  Alok Srivastava (India)  *

Jih-Luh Tang (Taiwan)  Shuichi Taniguchi (Japan)  Takanori Teshima (Japan)

Artit Ungkanont (Thailand)  Auro Viswabandya (India)  Jianmin Wang (China)

Jong-Ho Won (Korea)  Tong Wu (China)  Ming Yao (Taiwan)

Mei Zhang (China)

Honorary Members

Kerry Atkinson (Australia)  John Carter (New Zealand)  Dennis Confer (NMDP)

John Goldman (EBMT)  Alois Gratwohl (EBMT)  Geoffrey Hill (Australia)

Mary Horowitz (CIBMTR)  Dietger Niederwieser (EBMT)

Emeritus Members

Suresh H Advani (India)  Shigetaka Asano (Japan)  Lu Xian Cao (China)

Ardeshir Ghavamzadeh (Iran)  Surapol Issaragrisil (Thailand)  Saengsuree Jootar (Thailand)

Chun Choo Kim (Korea)  Dong Jip Kim (Korea)  Yoshihisa Kodera (Japan)

Dao-Pei Lu (China)  Tohru Masaoka (Japan)  Tan Binh Nguyen (Vietnam)

Philip Rowlings (Australia/New Zealand)  Tapan K Saikia (India)  Pattric Tan (Singapore)
Annual Congresses
Guidelines for the hosting of the APBMT annual congress

Planning and preparation

- APBMT Annual Congress is organized by APBMT in collaboration with the host country/society each year through an Organizing Committee and a Scientific Program Committee (SPC).
- The chair of the APBMT Board will be a Co-President of the Annual Congress along with a Co-President nominated by the host country.
- Both committees will function as per a schedule drawn up by the APBMT Secretariat for targets to be achieved to the dates of the congress.
- The Organizing Committee will have two Co-chairs - Chair of the APBMT Board/Board nominee with a Co-chair from the host country/society, and the equal number of members nominated by the APBMT Board and the host country/society.
- The Scientific Program Committee (SPC) of Congress will have two co-chairs - one local and one APBMT Executive Board (EB) nominated along with an equal number of local and EB nominated international members.

The scientific program will be planned according to the standard format:

- 1st day for APBMT standing committees and working group meetings- Industry symposia / CME program or educational symposia followed by 2 ½ days of the scientific program.
- The program should consist of three major tracks for physicians, nurses, and other specialists (such as laboratory diagnostics, cell and graft manipulation, pharmacists)
- The program should contain both educational sessions and sessions covering recent topics/advances in hematopoietic cell transplantation and related fields.
- Each session has a theme on which there could be 3-4 talks in up to 90min.
- The speakers of each topic should be decided by SPC with the invitation letters to be sent by the Co-Chairs of SPC.
- Try to recruit speakers from APBMT participating countries/regions as much as possible (at least 50%) – giving representation to as many countries from Asian-Pacific (AP) regions AP as possible. Criteria for selection of speakers to be defined and followed.
- No AP country/region should have more than 10% of the total number of speakers from Asian Pacific regions in the entire Scientific Program; however, it is acceptable for a host country to have more speakers depending on their suitability but not exceeding 20% of the total.
The term “speaker” here is determined as the one listed in the Scientific Program (including Plenary and Educational Session) prepared by the SPC but excluding sponsored symposia.

The meeting should be organized as a hybrid meeting but with major emphasis on a physical meeting when circumstances permit.

**Funding**

- APBMT office may directly collect funding support from the international division of a multinational company (MNC), and the local host country will collect the support from domestic divisions of MNCs / local companies.
- The overall cost of hosting the Annual Congress will be shared between APBMT and the host country in the same proportion as the total funds collected from all sources.
- Left over funds after meeting all costs of the Annual Congress will be shared between APBMT and the host country in the same proportion as the overall fund collected.
- The budget for the Annual Congress should therefore be jointly decided between APBMT and the host country through the Organizing Committee and the Co-Presidents.

**After the congress**

- The hosting country must submit the followings to APBMT Secretariat after the meeting
  - Generate and report the financials
  - Submit a list of all attendees (names, countries and email address if possible)
  - Provide all abstracts for uploading on the Blood Cell Therapy website. The permission should be obtained from presenters when they were submitted
  - Provide photos and PowerPoint presentations made during the Congress for uploading the APBMT website after due permissions from the speakers.
## Previous Congresses

<table>
<thead>
<tr>
<th>No</th>
<th>Year</th>
<th>City</th>
<th>Presidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>1990</td>
<td>Beijing</td>
<td>Lu Xian Cao</td>
</tr>
<tr>
<td>2nd</td>
<td>1991</td>
<td>Nagoya</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>3rd</td>
<td>1992</td>
<td>Osaka</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>4th</td>
<td>1994</td>
<td>Fukuoka</td>
<td>Tohru Masaoka</td>
</tr>
<tr>
<td>5th</td>
<td>1996</td>
<td>Seoul</td>
<td>Dong Jip Kim</td>
</tr>
<tr>
<td>6th</td>
<td>1998</td>
<td>Taipei</td>
<td>Yao-Chang Chen</td>
</tr>
<tr>
<td>7th</td>
<td>2000</td>
<td>Bangkok</td>
<td>Surapol Issaragrisil</td>
</tr>
<tr>
<td>8th</td>
<td>2002</td>
<td>Mumbai</td>
<td>Suresh Advani</td>
</tr>
<tr>
<td>9th</td>
<td>2004</td>
<td>Tehran</td>
<td>Ardesher Ghavamzadeh</td>
</tr>
<tr>
<td>10th</td>
<td>2005</td>
<td>Hangzhou</td>
<td>Dao-Pei Lu</td>
</tr>
<tr>
<td>11th</td>
<td>2006</td>
<td>Nagoya</td>
<td>Yoshihisa Kodera</td>
</tr>
<tr>
<td>12th</td>
<td>2007</td>
<td>Beijing</td>
<td>Dao-Pei Lu</td>
</tr>
<tr>
<td>13th</td>
<td>2008</td>
<td>Taipei</td>
<td>Po-Min Chen</td>
</tr>
<tr>
<td>14th</td>
<td>2009</td>
<td>Seoul</td>
<td>Chun-Choo Kim</td>
</tr>
<tr>
<td>15th</td>
<td>2010</td>
<td>Phuket</td>
<td>Saengsuree Jootar</td>
</tr>
<tr>
<td>16th</td>
<td>2011</td>
<td>Sydney</td>
<td>David Ma / Philip Rowlings</td>
</tr>
<tr>
<td>17th</td>
<td>2012</td>
<td>Hyderabad</td>
<td>Tapan K Saikia / Alok Srivastava</td>
</tr>
<tr>
<td>18th</td>
<td>2013</td>
<td>Ho Chi Minh City</td>
<td>Tan Binh Nguyen</td>
</tr>
<tr>
<td>19th</td>
<td>2014</td>
<td>Hangzhou</td>
<td>He Huang / Xiaojun Huang</td>
</tr>
<tr>
<td>20th</td>
<td>2015</td>
<td>Okinawa</td>
<td>Shinichiro Okamoto</td>
</tr>
<tr>
<td>21st</td>
<td>2016</td>
<td>Singapore</td>
<td>William YK Hwang / Chng Wee Joo/Aloysius Ho</td>
</tr>
<tr>
<td>22nd</td>
<td>2017</td>
<td>Tehran</td>
<td>Ardesher Ghavamzadeh</td>
</tr>
<tr>
<td>23rd</td>
<td>2018</td>
<td>Taipei</td>
<td>Ming Yao / Jih-Luh Tang</td>
</tr>
<tr>
<td>24th</td>
<td>2019</td>
<td>Busan</td>
<td>Jong Wook Lee / Jong-Ho Won</td>
</tr>
<tr>
<td>25th</td>
<td>2020</td>
<td>APBMT/ISBMT (Virtual)</td>
<td>Mammen Chandy</td>
</tr>
<tr>
<td>26th</td>
<td>2021</td>
<td>Chang Mai (Hybrid)</td>
<td>Artit Ungkanont</td>
</tr>
</tbody>
</table>
Future Congresses

- The 27th Annual Congress will be hosted by Indian Society for Blood and Marrow Transplantation (ISBMT) in 2022
  October 6 to 9, 2022
  Kochi, India
<table>
<thead>
<tr>
<th>Country</th>
<th>2012(INDIA)</th>
<th>2013(VIETNAM)</th>
<th>2014(CHINA)</th>
<th>2015(JAPAN)</th>
<th>2016(SINGAPORE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>118</td>
<td>375</td>
<td>China</td>
<td>646</td>
<td>Singapore</td>
</tr>
<tr>
<td>China</td>
<td>66</td>
<td>82</td>
<td>Japan</td>
<td>31</td>
<td>China</td>
</tr>
<tr>
<td>Japan</td>
<td>19</td>
<td>Korea</td>
<td>Taiwan</td>
<td>24</td>
<td>Japan</td>
</tr>
<tr>
<td>Korea</td>
<td>15</td>
<td>Japan</td>
<td>Korea</td>
<td>16</td>
<td>Korea</td>
</tr>
<tr>
<td>Vietnam</td>
<td>12</td>
<td>Taiwan</td>
<td>United States</td>
<td>17</td>
<td>Singapore</td>
</tr>
<tr>
<td>Australia</td>
<td>11</td>
<td>Thailand</td>
<td>India</td>
<td>9</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Germany</td>
<td>8</td>
<td>Hong Kong</td>
<td>Singapore</td>
<td>9</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Taiwan</td>
<td>7</td>
<td>Belgium</td>
<td>Ausraalia</td>
<td>7</td>
<td>India</td>
</tr>
<tr>
<td>Iran</td>
<td>6</td>
<td>Singapore</td>
<td>Mongolia</td>
<td>7</td>
<td>Thailand</td>
</tr>
<tr>
<td>USA</td>
<td>6</td>
<td>France</td>
<td>UK</td>
<td>5</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Singapore</td>
<td>4</td>
<td>India</td>
<td>Hong Kong</td>
<td>4</td>
<td>USA</td>
</tr>
<tr>
<td>Philippines</td>
<td>3</td>
<td>Australia</td>
<td>Philippines</td>
<td>4</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>2</td>
<td>Iran</td>
<td>Vietnam</td>
<td>4</td>
<td>Australia</td>
</tr>
<tr>
<td>Belgium</td>
<td>2</td>
<td>United States</td>
<td>France</td>
<td>3</td>
<td>Philippines</td>
</tr>
<tr>
<td>France</td>
<td>2</td>
<td>Germany</td>
<td>Iran</td>
<td>3</td>
<td>UK</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>2</td>
<td>Mongolia</td>
<td>Thailand</td>
<td>3</td>
<td>Germany</td>
</tr>
<tr>
<td>Mongolia</td>
<td>2</td>
<td>Spain</td>
<td>Germany</td>
<td>2</td>
<td>Iran</td>
</tr>
<tr>
<td>Canada</td>
<td>1</td>
<td>Malaysia</td>
<td>Myanmar</td>
<td>2</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Italy</td>
<td>1</td>
<td>Philippines</td>
<td>Pakistan</td>
<td>2</td>
<td>Bangladesh</td>
</tr>
<tr>
<td>Myanmar</td>
<td>1</td>
<td>Indonesia</td>
<td>Bangladesh</td>
<td>1</td>
<td>Cambodia</td>
</tr>
<tr>
<td>Nepal</td>
<td>1</td>
<td>Ireland</td>
<td>Indonesia</td>
<td>1</td>
<td>Canada</td>
</tr>
<tr>
<td>Sweden</td>
<td>1</td>
<td>Myanmar</td>
<td>Lebanon</td>
<td>1</td>
<td>France</td>
</tr>
<tr>
<td>UK</td>
<td>1</td>
<td>Netherlands</td>
<td>Malaysia</td>
<td>1</td>
<td>Italy</td>
</tr>
<tr>
<td>Missing</td>
<td>3</td>
<td>Sweden</td>
<td>South Africa</td>
<td>1</td>
<td>Mongolia</td>
</tr>
</tbody>
</table>

<p>| Total        | 294         | UK            | Spain       | 1           | Myanmar        |
| %            | Total       | 736           | Pakistan    | 1           | Qatar          |
| Domestic     | 40%         | %             | Missing     | 1           | Canada         |
| Foreign      | 60%         | Domestic      | Total       | 567         | Nepal          |
|             |             | Foreign       | %           | New Zealand  | Spain          |
|             |             |               |             |             | Switzerland    |
|             |             |               |             |             | Total          |
| Domestic     | 33%         |              |             |             |                |
| Foreign      | 67%         |              |             |             |                |</p>
<table>
<thead>
<tr>
<th>2017(IRAN)</th>
<th>2018(TAIWAN)</th>
<th>2019(KOREA) *</th>
<th>2020(INDIA) (Virtual)**</th>
<th>2021(THAILAND) (Hybrid)***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iran 565</td>
<td>Taiwan 330</td>
<td>Korea 762</td>
<td>India 822</td>
<td>Thailand 525</td>
</tr>
<tr>
<td>China 32</td>
<td>China 90</td>
<td>China 125</td>
<td>China 173</td>
<td>Singapore 48</td>
</tr>
<tr>
<td>USA 4</td>
<td>Japan 66</td>
<td>Japan 47</td>
<td>Philippines 98</td>
<td>Japan 31</td>
</tr>
<tr>
<td>Germany 4</td>
<td>Korea 33</td>
<td>Taiwan 46</td>
<td>Vietnam 68</td>
<td>China 26</td>
</tr>
<tr>
<td>Japan 3</td>
<td>Singapore 32</td>
<td>India 37</td>
<td>Japan 67</td>
<td>India 18</td>
</tr>
<tr>
<td>Thailand 3</td>
<td>Vietnam 29</td>
<td>Indonesia 22</td>
<td>Singapore 36</td>
<td>Hong Kong 17</td>
</tr>
<tr>
<td>Qatar 3</td>
<td>Thailand 21</td>
<td>Singapore 22</td>
<td>Korea, South 28</td>
<td>Malaysia 17</td>
</tr>
<tr>
<td>France 2</td>
<td>Hong Kong 18</td>
<td>Malaysia 17</td>
<td>Burma 27</td>
<td>Australia 11</td>
</tr>
<tr>
<td>Italy 2</td>
<td>USA 15</td>
<td>USA 17</td>
<td>Iran 26</td>
<td>Bangladesh 11</td>
</tr>
<tr>
<td>Belgium 1</td>
<td>Philippines 13</td>
<td>Vietnam 16</td>
<td>Malaysia 23</td>
<td>Vietnam 11</td>
</tr>
<tr>
<td>India 1</td>
<td>India 11</td>
<td>Germany 11</td>
<td>Australia 21</td>
<td>Philippines 10</td>
</tr>
<tr>
<td>Turkey 1</td>
<td>Malaysia 8</td>
<td>Hong Kong 10</td>
<td>Thailand 20</td>
<td>USA 9</td>
</tr>
<tr>
<td>UK 1</td>
<td>Indonesia 7</td>
<td>Thailand 9</td>
<td>Bangladesh 17</td>
<td>UK 8</td>
</tr>
<tr>
<td>Switzerland 1</td>
<td>Sri Lanka 5</td>
<td>Pakistan 8</td>
<td>United Kingdom 12</td>
<td>Taiwan 5</td>
</tr>
<tr>
<td>Total 625</td>
<td>UK 5</td>
<td>Philippines 7</td>
<td>Taiwan, China 11</td>
<td>Germany 4</td>
</tr>
<tr>
<td>%</td>
<td>Germany 4</td>
<td>Australia 5</td>
<td>United States 10</td>
<td>France 2</td>
</tr>
<tr>
<td>Domestic 90</td>
<td>Canada 3</td>
<td>Egypt 3</td>
<td>Germany 9</td>
<td>México 2</td>
</tr>
<tr>
<td>Foreign 10</td>
<td>Mongolia 3</td>
<td>France 3</td>
<td>Sri Lanka 9</td>
<td>Argentina 1</td>
</tr>
<tr>
<td>Myanmar 3</td>
<td>Turkey 3</td>
<td>Hong Kong, China 8</td>
<td>Austria 1</td>
<td></td>
</tr>
<tr>
<td>Romania 2</td>
<td>UK 3</td>
<td>Indonesia 6</td>
<td>Canada 1</td>
<td></td>
</tr>
<tr>
<td>Cambodia 1</td>
<td>Switzerland 2</td>
<td>Mongolia 6</td>
<td>Iran 1</td>
<td></td>
</tr>
<tr>
<td>France 1</td>
<td>Spain 2</td>
<td>Canada 4</td>
<td>Italy 1</td>
<td></td>
</tr>
<tr>
<td>Iran 1</td>
<td>Bangladesh 2</td>
<td>France 3</td>
<td>Myanmar 1</td>
<td></td>
</tr>
<tr>
<td>Netherlands 1</td>
<td>Austria 1</td>
<td>Italy 2</td>
<td>Pakistan 1</td>
<td></td>
</tr>
<tr>
<td>North Korea 1</td>
<td>Brazil 1</td>
<td>Nepal 2</td>
<td>Portugal 1</td>
<td></td>
</tr>
<tr>
<td>Spain 1</td>
<td>Cambodia 1</td>
<td>Belgium 1</td>
<td>UAE 1</td>
<td></td>
</tr>
<tr>
<td>Total 716</td>
<td>Canada 1</td>
<td>Cambodia 1</td>
<td>Total 778</td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>Italy 1</td>
<td>Ireland 1</td>
<td>Domestic 67</td>
<td></td>
</tr>
<tr>
<td>Domestic 46</td>
<td>Myanmar 1</td>
<td>Netherlands 1</td>
<td>Domestic 67</td>
<td></td>
</tr>
<tr>
<td>Foreign 54</td>
<td>Nepal 1</td>
<td>Sweden 1</td>
<td>Foreign 33</td>
<td></td>
</tr>
<tr>
<td>Netherlands 1</td>
<td>Switzerland 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland 1</td>
<td>United Arab Emirates 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sri Lanka 1</td>
<td>Total 1543</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uzbekistan 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total 1206</td>
<td>Domestic 53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>Foreign 47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domestic 63</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign 37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*APBMT 2019 with ICBMT 2019 (International Congress of Blood and Marrow Transplantation)
**APBMT 2020 with ISBMT (Indian Society for Blood & Marrow Transplantation)
***APBMT 2021 with TSH (Thai Society of Hematology)
APBMT Registry Committee

APBMT has long collected HSCT activity and outcome data through APBMT Data Center. To promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014 and it officially started operations in October 2015. APBMT Data Center was integrated into the Committee. In 2021, rules for the appointment of members in the Committee Terms changed. The rules now state that “Members are nominated by the Scientific Committee members or the Registry Committee members in each country/region, and approved by the Executive Board. The decision will be reported to the Scientific Committee members.” Four new members joined according to this rule.

Since the Committee began the work, four important official documents have been finalized.

- Protocol
- Letter of Commitment
- Informed Consent for Patients
- Detailed Rules for Data Usage and Authorship
  (Revised version 2.0 was approved on July 16, 2020)

Based on these documents, committee members work hard:

- To perform APBMT Activity Survey and Outcome Registry annually
- To support data collection in participating countries/regions
- To manage and analyze the collected data
- To optimize the data usage
- To support clinical researches using collected data

For further achievement, members have the web conference bi-monthly.

[About Activity Survey]
The APBMT Activity Survey has been performed annually since 2007 (HSCT data from 2005). This survey collects the number of transplantations sorted by the donor sources and diseases in each country/region.
The following figure shows how the data is collected.
The method of submission is different in each country/region. As shown in the figure above, data from China, India, Iran, Japan, Korea, Malaysia, and Taiwan was submitted through their respective national registry. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Indonesia, Myanmar, the Philippines, Sri Lanka, and Thailand, data was collected by a designated contact person and submitted to Data Center. Data Center has direct contact with significant transplantation centers and receives data from Hong Kong, Mongolia, Nepal, Pakistan, Singapore, and Vietnam. Data Center compiles all data collected in each of these six countries/regions, and gathered data is available for each country/region to use as national data.

The results of the Activity Survey are put on the APBMT website:

https://www.apbmt.org/research/registry/survey

[About Outcome Registry]
APBMT Registry Committee and Data Center have been collecting the HSCT outcome data of each patient. The basic dataset structure is called the Least Minimum Dataset (LMD), and three methods are available for sending data to Data Center depending on
the situation in each country/region.

- The simplified Excel forms made by APBMT Data Center based on the EBMT MED-A or the CIBMTR TED
- Receiving data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR
- The electronic data capture (EDC) system using REDCap®

When the Registry/Society in participating counties/regions starts to submit HSCT outcome data to APBMT, a Non-Disclosure Agreement (NDA) is signed between APBMT and the Registry/Society when requested. In addition, APBMT Registry Committee stipulates detailed rules for data usage so that the submitted data will not be disclosed without the consent of the Committee.

*The following countries/regions are building up their systems for submitting outcome data: Indonesia, Iran, Korea, Malaysia, and Thailand*
## Registry Committee Member List

<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairperson</strong></td>
<td>Yoshiko Atsuta</td>
<td>Japan</td>
</tr>
<tr>
<td><strong>Deputy Chairpersons</strong></td>
<td>Anthony Dodds</td>
<td>Australia/New Zealand</td>
</tr>
<tr>
<td></td>
<td>Aloysius Ho</td>
<td>Singapore</td>
</tr>
<tr>
<td><strong>Members</strong></td>
<td>Mafruha Akter</td>
<td>Bangladesh</td>
</tr>
<tr>
<td></td>
<td>Pheng Bora</td>
<td>Cambodia</td>
</tr>
<tr>
<td></td>
<td>Xiao Jun Huang</td>
<td>China</td>
</tr>
<tr>
<td></td>
<td>Liu Kaiyan</td>
<td>China</td>
</tr>
<tr>
<td></td>
<td>Lv Meng</td>
<td>China</td>
</tr>
<tr>
<td></td>
<td>Joycelyn Sim</td>
<td>Hong Kong</td>
</tr>
<tr>
<td></td>
<td>Vincent Lee</td>
<td>Hong Kong</td>
</tr>
<tr>
<td></td>
<td>Alok Srivastava</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td>Kavitha M.L</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td>Damai Santosa</td>
<td>Indonesia</td>
</tr>
<tr>
<td></td>
<td>Amir Hamidieh</td>
<td>Iran</td>
</tr>
<tr>
<td></td>
<td>Shinichiro Okamoto</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Yachiyo Kuwatsuka</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Joon Ho Moon</td>
<td>Korea</td>
</tr>
<tr>
<td></td>
<td>Kim Wah Ho</td>
<td>Malaysia</td>
</tr>
<tr>
<td></td>
<td>Batsukh Khishigjargal</td>
<td>Mongolia</td>
</tr>
<tr>
<td></td>
<td>Aye Aye Gyi</td>
<td>Myanmar</td>
</tr>
<tr>
<td></td>
<td>Bishesh Poudyal</td>
<td>Nepal</td>
</tr>
<tr>
<td></td>
<td>Tasneem Farzana</td>
<td>Pakistan</td>
</tr>
<tr>
<td></td>
<td>Marjorie Rose Bravo</td>
<td>Philippines</td>
</tr>
<tr>
<td></td>
<td>Prasad Abeysinghe</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td></td>
<td>Devinda Jayathilake</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td></td>
<td>Bor-Sheng Ko</td>
<td>Taiwan</td>
</tr>
<tr>
<td></td>
<td>Hui-Fen Chiang</td>
<td>Taiwan</td>
</tr>
<tr>
<td></td>
<td>Po-Nan Wang</td>
<td>Taiwan</td>
</tr>
<tr>
<td></td>
<td>Ming Yao</td>
<td>Taiwan</td>
</tr>
<tr>
<td></td>
<td>Artit Ungkanont</td>
<td>Thailand</td>
</tr>
<tr>
<td></td>
<td>Suradej Hongeng</td>
<td>Thailand</td>
</tr>
<tr>
<td></td>
<td>Huynh Van Man</td>
<td>Vietnam</td>
</tr>
<tr>
<td></td>
<td>Phu Chi Dung</td>
<td>Vietnam</td>
</tr>
<tr>
<td><strong>Data Center</strong></td>
<td>Minako Iida</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Yukari Nakao</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Hiroe Namizaki</td>
<td>Japan</td>
</tr>
</tbody>
</table>
Nuclear Accident Management (NAM) Committee
Nuclear Accident Management (NAM) Committee

The APBMT Nuclear Accident Management Committee (NAM Committee) was established at the APBMT Annual Congress in Hyderabad, India, in 2012 to:

1) investigate what is happening in this region and what is being done around the world in the field of a nuclear accident
2) facilitate cooperation with other societies such as EBMT, ASTCT, and WBMT
3) establish an APBMT Nuclear Accident Registry
4) establish a training program
5) prepare the standard operating procedure for the handling of the nuclear accident in our region

Since then, the NAM meeting has been held every year at the Annual Congress, and the final draft of the NAM guidelines, written by co-chairs (Drs. Velu Nair and Hyo Rak Lee), was approved by the APBMT Scientific Committee in 2020.

https://www.apbmt.org/education/guideline-nam

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Velu Nair</td>
<td>India</td>
</tr>
<tr>
<td>Chair</td>
<td>Hyo Rak Lee</td>
<td>Korea</td>
</tr>
<tr>
<td>Past Chair</td>
<td>Alok Srivastava</td>
<td>India</td>
</tr>
<tr>
<td>Past Chair</td>
<td>David Ma</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Mohiuddin Khan</td>
<td>Bangladesh</td>
</tr>
<tr>
<td></td>
<td>Koichi Miyamura</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Syuuichi Taniguchi</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Khishigjargal Batsukh</td>
<td>Mongolia</td>
</tr>
<tr>
<td></td>
<td>Aye Aye Gyi</td>
<td>Myanmar</td>
</tr>
<tr>
<td></td>
<td>Simit Sapkota</td>
<td>Nepal</td>
</tr>
<tr>
<td></td>
<td>Prasad Abeysinghe</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td></td>
<td>Phu Chi Dung</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Chairman, Executive Board</td>
<td>Shinichiro Okamoto</td>
<td>Japan</td>
</tr>
</tbody>
</table>
Executive Board
Executive Board Activities

For smooth management of the international society, Executive Board members have official web conferences every month and ad-hoc web conferences when needed. The main topics discussed in the Executive Board web conferences are:

- Working together with the host country/region to prepare for each annual congress
  - Making up the scientific program
  - Nomination of speakers
  - Management of funding
- Nominating the host country for the upcoming annual congress
- Amendment of the Bylaws and membership definition
- Rulemaking for each committee
- Sponsorship contract with the third parties/companies
- Education/training of physicians/nurses involved in HSCT and cell therapy
- Collaboration with ASTCT, EBMT, WBMT, and other related societies in the field of HSCT
  - Nomination of APBMT members to the Harmonization Definition Task Force (ASTCT/EBMT)
  - Nomination of APBMT speakers for the TCT meeting, EBMT, WBMT Webinars, and EBMT COVID-19 SUMMIT
- Membership control
  - Review of membership application forms
  - Membership fees
  - Dual membership between ASTCT
- Solving the problems with advice to each committee (Registry Committee, Editorial Board of Blood Cell Therapy, Financial Committee)
- Conduct survey research if needed
  - Survey on Cancer Immunology in Asian Countries (JAPAN)
  - Survey for the presentation of “Quality and Accreditation for Cellular Therapy: A Global Perspective” (WBMT)
  - Survey for COVID-19 impacts on HSCT in 2020 (EBMT summit)
  - Antiemetics survey (Nutrition Support WG)
Executive Board Members

Shinichiro Okamoto
Chairman
Japan

Alok Srivastava
Vice Chairman
India

Jong-Wook Lee
Korea

David Ma
Australia

Amir Hamidieh
Iran

William Hwang
Singapore

He Huang
China
Collaboration with Other International Registries

WBMT
ASTCT
EBMT
WBMT (Worldwide Network for Blood & Marrow Transplantation)

APBMT is one of the first founding societies of WBMT and has collaborated with other member societies such as CIBMTR, EBMT, and WMDA to operate WBMT since 2007.

Dr. Yoshihisa Kodera (Japan) and Dr. Jeff Szer (Australia) have served as the WBMT president. Many members in APBMT played important roles in the Standing Committees in 2020: Co-chair of Education & Dissemination Committee: Yoshihisa Kodera, Co-chair of Global Emergencies/Nuclear Accident Management Committee: David Ma, Co-chair of Transplant Centre/Recipient Committee: Yoshiko Atsuta.

In addition, APBMT Data Center has submitted the Activity Survey data every year to contribute to the WBMT Global Transplant Activity Survey.

ASTCT (American Society for Transplantation and Cellular Therapy)

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership. APBMT members who applied for this membership could receive many benefits from ASTCT. APBMT and ASTCT will continue to proceed with the second and third collaboration projects.

EBMT (European Society for Blood and Marrow Transplantation)

With the cooperation of EBMT, APBMT could set up an original booth at the annual meeting for the past few years. APBMT could exhibit the activities and contact with registered members and non-members there. With regard to a project for the establishment of the APBMT Center Standards, we could get informative advice from JACIE members.
History of International Scientific Symposia

2021

October, APBMT 2021 hybrid (Thailand)

Presidential Symposium: Design the future of HCT Societies
Chairpersons: S. Okamoto, A. Ungkanont
  ● EBMT perspective (N. Kroger)
  ● ASTCT perspective (S. Davies)
  ● WBMT perspective (H. Greinix)
  ● APBMT perspective (S. Okamoto)

July, FACT/WBMT Webinar

Quality and Accreditation for Cellular Therapy: A Global Perspective
  ● Establishing an HSCT Program: Essential Requirements (D. Niderwieser)
  ● Development of a Quality Program in the Asia-Pacific Region (A. Srivastava)
  ● FACT-JACIE Accreditation in Latin America (C. Bachier)

June, EBMT Summit on COVID-19

Clinical Impact and management in HSCT patient 1, Activity impact and clinical outcome
Chairs: P. Ljungman, M. Mikulska
  ● EBMT experience (P. Ljungman)
  ● USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center (G. Papanicolau)
  ● Asian Pacific BM Society experience (APBMT) (W. Hwang)

April, WBMT/EBMT Webinar

Haplo-Identical HSCT, Methods and Practices Around the Globe
Moderators: H. Greinix, N. Kröger
  ● Haploidentical HSCT practice in Europe (A. Bacigalupo)
  ● Haploidentical HSCT practice in Asia (XJ. Huang)
  ● Haploidentical HSCT practice in North America (L. Luznik)

March, EBMT (virtual)

Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics
Co-Charis: N. Kröger, S Davies, M. Riches, A. Srivastava
  ● US Experience: Pandemics and Transplantation/Cell therapy (A. Waghmare)
  ● The CIBMTR COVID Experience: Challenges for research and how COVID has changed transplant practice (M. Riches)
The IDWP-EBMT COVID 19 Experience (R. Cámara)
Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment during COVID 19 pandemic (Y. Hu)

**February, ASTCT (Digital Experience)**

*WBMT Concurrent: Transplant During a Worldwide Crisis: Lessons Learned Across the World*

Co-Chairs: W. Saber, M. Aljurf
- The Latin American Bone Marrow Transplantation Group (LABMT) Experience (A. Seber)
- HSCT Challenges and Solutions Under COVID-19: The Experience from China (X. Huang)
- The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group Experience (RE. Fakih)

**2020**

**October, APBMT 2020 virtual (India)**

*Presidential Symposium on HSCT and Covid-19*

Chairpersons: S. Okamoto, N. Kroeger, A. Srivastava
Moderator: S. Damodar
- HSCT in the Covid-19 Era- the Chinese Experience (H. Huang)
- Practice of HSCT in North America in COVID-19 Era (N. Majhail)
- Practice of HSCT in Europe in COVID-19 Era (P. Ljungman)
- Managing HSCTs in the context of COVID-19 pandemic - A LMIC perspective (S. Damodar)

**May, WBMT Live Webinar (Online)**

*COVID-19 and stem cell transplantation, a Worldwide perspective:*

Moderators: Y Kodera, S Galeano
- Management of donors during the pandemic (F. Alfraih)
- Transplant recipients; COVID-19 guidelines and real-world (C. Machado)
- Chinese experience (H. Huang)
- Data from the EBMT registry during COVID-19 (P. Ljungman)
- Chimeric Antigen Receptor T Cell Therapy during COVID-19 (MA. Perales)

**2019**

**August, APBMT (Korea)**

*ASTCT/EBMT/WBMT/APBMT Joint Session:*

Co-Chairs: JW Lee, S. Okamoto
- GvHD Prophylaxis with Post Cy after Haplo-Identical, Matched Unrelated and HLA-Identical Sibling Transplantation (N. Kroger)
- Future Changes in Stem Cell Transplantation and Cellular Therapy: Safer, Less Toxic and Less Costly Approaches (D. Weisdorf)
- Novel Approaches for Treating and Preventing GvHD (JF DiPersio)
- Design the Future of Hematopoietic Cell Transplantation (HCT) in Asia-Pacific Countries/Regions (S. Okamoto)

2018

**November, APBMT (Taiwan)**

*ASBMT / EBMT / WBMT / APBMT Joint Symposium: Past, Now, and Future of Hematopoietic Stem Cell Transplantation*

Co-Chairs: M. Yao, S. Okamoto

- Hematopoietic Stem Cell Transplantation: Where have we come from and where do we go? (J. Gajewski)
- Past, now and future of hematopoietic stem cell transplantation (EBMT prospective) (N. Kroger)
- How does the past predict the future of allogeneic transplantation: lessons for the field? (D. Weisdorf)
- How the APBMT is facing the challenge (S. Okamoto)

**September, The 5th WBMT Workshop (Beijing, China)**

*International Experience and Data Sharing to Improve Access and Outcomes of Transplantation*

1. Importance of creating the HSCT global outcome registration system
   - Global perspective of HSCT & registration (J. Szer)
   - WBMT Global Survey & registration (D. Niederwieser)
   - CIBMTR perspective of HSCT and registration (M Pasquini)
   - HSC Donor Registries: Challenges and Perspectives (C. Muller)
   - APBMT perspective: Importance of Outcome Data Sharing in Asian Pacific Region (Y. Kodera)
   - Current Activity Survey in the AP region (M. Iida)
   - Outcome Registry Current Status and future perspectives (Y. Atsuta)
   - Chinese perspective of HSCT and Activity Surveys; Difficulties in Data collection (XJ. Huang)

2. International Standards and Accreditation
   - Steps towards international accreditation: Lessons learned (S. Okamoto)
   - Addressing unproven cellular therapies (M. Koh)
April, WBMT/AfBMT (Morocco)
First Meeting of the African Blood and Marrow Transplantation Group: SCT in bone
marrow failure
Co-Chairs: N. Novitzky, N. Khoubila
  ● Recent Progress in Diagnosis and Treatment of Inherited Bone Marrow Failure
    (S. Kojima)
  ● Acquired (S. Osman Ahmed)

October, APBMT (Iran)
APBMT / WBMT Joint Session: Transplantation reports in the Asian pacific region &
the progress of BMT in the world and Asian pacific region
Co-Chairs: A. Ghavamzadeh, S. Okamoto
  ● The progress of BMT in the Islamic Republic of Iran (A. Ghavamzadeh)
  ● The report of transplantation in all 15 BMT centers of Iran in the last five years
    (A. Hajifathali)
  ● The current status and future challenges of the Asia-Pacific Blood and Marrow
    Transplantation Group (APBMT) (S. Okamoto)
  ● The history, current status and future trends of WBMT (Y. Kodera)
  ● The report of transplantation in China five recent years (H. Huang)
  ● The advance of HSCT after the enforcement of “The Act for Appropriate
    Provision of Hematopoietic Stem Cells to be Used in Transplantations” in Japan
    (Y. Kodera)
  ● Outcome of autologous hematopoietic stem cell transplants for multiple
    myeloma in a single center in Sri Lanka (L. Gooneratne)
  ● The report of transplantation in Malaysia in five recent years (OT. Chuan)
Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly.

Aims and scope: Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy

Online ISSN: 2432-7026

Journal homepage: https://bct.apbmt.org/
### Submission status of Blood Cell Therapy as of December 31, 2021

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Submitted</strong></td>
<td>2</td>
<td>11</td>
<td>17</td>
<td>23</td>
<td>25</td>
</tr>
<tr>
<td><strong>Total Decisioned</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accept</td>
<td>1</td>
<td>9</td>
<td>12</td>
<td>17</td>
<td>21</td>
</tr>
<tr>
<td>Reject</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Ongoing</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Acceptance Rate</strong></td>
<td>50%</td>
<td>82%</td>
<td>71%</td>
<td>74%</td>
<td>(84%)</td>
</tr>
<tr>
<td><strong>Article type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State of the Art</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Original Article</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Review Article</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Case Report</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Short Communication</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Survey Report</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guideline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

### Authors by country/region

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Australia</strong></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>Bangladesh</strong></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Canada</strong></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>China</strong></td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td><strong>India</strong></td>
<td></td>
<td></td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td><strong>Indonesia</strong></td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td><strong>Japan</strong></td>
<td>1</td>
<td>7</td>
<td>6</td>
<td>8</td>
<td>6</td>
<td>28</td>
</tr>
<tr>
<td><strong>Korea</strong></td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td><strong>Malaysia</strong></td>
<td></td>
<td>1</td>
<td>2</td>
<td>1</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td><strong>Myanmar</strong></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Pakistan</strong></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Philippines</strong></td>
<td>1</td>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td><strong>Singapore</strong></td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Country</td>
<td>Count</td>
<td>Page</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Editorial Award of Blood Cell Therapy 2020**

**Minako Iida**  
Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation  
Volume 3 (2020) Issue 1 No.3 Pages 11-17  
https://doi.org/10.31547/bct-2019-011

**Takahiko Sato**  
Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies  
Volume 3 (2020) Issue 4 No.4 Pages 84-91  
https://doi.org/10.31547/bct-2020-007

**Yoo Jin Lee**  
Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation  
Volume 3 (2020) Issue 2 No.2 Pages 22-31  
https://doi.org/10.31547/bct-2019-015
# Editorial Board Member List

<table>
<thead>
<tr>
<th>Name</th>
<th>Commission</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoshiki Akatsuka</td>
<td>Editor-in-Chief</td>
<td>Japan</td>
</tr>
<tr>
<td>Tatsuo Ichinohe</td>
<td>Deputy Editor-in-Chief</td>
<td>Japan</td>
</tr>
<tr>
<td>Jeffrey Szer</td>
<td>Associate Editors</td>
<td>Australia</td>
</tr>
<tr>
<td>David Yeung</td>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td>Haowen Xiao</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Navin Khattri</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Auro Viswabandya</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Maryam Behfar</td>
<td></td>
<td>Iran</td>
</tr>
<tr>
<td>Ayami Yoshimi</td>
<td></td>
<td>Germany /Japan</td>
</tr>
<tr>
<td>Satoshi Takahashi</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Junya Kanda</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Shinichiro Okamoto</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Jae Yong Kwak</td>
<td></td>
<td>Korea</td>
</tr>
<tr>
<td>Hee-Je Kim</td>
<td></td>
<td>Korea</td>
</tr>
<tr>
<td>Mickey Boon Chai Koh</td>
<td></td>
<td>Singapore</td>
</tr>
<tr>
<td>William YK Hwang</td>
<td></td>
<td>Singapore</td>
</tr>
<tr>
<td>Mei Zhang</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Yuqian Sun</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Alok Srivastava</td>
<td></td>
<td>India</td>
</tr>
<tr>
<td>Amir Hamidieh</td>
<td></td>
<td>Iran</td>
</tr>
<tr>
<td>Mahmoud Aljurf</td>
<td></td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>Daniel Weisdorf</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Minako Iida</td>
<td>Editorial Office</td>
<td>Japan</td>
</tr>
<tr>
<td>Yukari Nakao</td>
<td>Editorial Office</td>
<td>Japan</td>
</tr>
<tr>
<td>Hiroe Namizaki</td>
<td>Editorial Office</td>
<td>Japan</td>
</tr>
</tbody>
</table>

*random order

## Information for Submission

Manuscript submission rules for Authors: [https://bct.apbmt.org/for_authors/](https://bct.apbmt.org/for_authors/)

Editorial Policies: [https://bct.apbmt.org/editorial_policies/](https://bct.apbmt.org/editorial_policies/)

Guide for Reviewers: [https://bct.apbmt.org/for_reviewers/](https://bct.apbmt.org/for_reviewers/)

Submission: [https://mc.manuscriptcentral.com/bct](https://mc.manuscriptcentral.com/bct)
List of the Accepted Articles (As of November 25, 2021)

**Original Article**

**Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase hematopoietic cell transplantation**

Noriyasu Fukushima1,2,3, Satoshi Tomiyasu2, Yoshinori Uji2, Masako Yokoo3, Takeru Shindo3, Yasushi Kubota3, Toshihiko Ando3, Kensuke Kojima3, Eisaburo Sueoka4, Tatsuo Ichinohe1, Shinya Kimura3

1Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. 2Department of Medical Science Technology, School of Health Sciences at Fukuoka, International University of Health and Welfare, Okawa, Japan. 3Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. 4Department of Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Blood Cell Therapy Vol.1 Issue.1 No.1 Pages 1-8

Submitted: December 19, 2017  Accepted: July 7, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2017-002

**Review Article**

**Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia**

Sung-Eun Lee and Jong Wook Lee

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Blood Cell Therapy Vol.1 Issue.1 No.2 Pages 9-17

Submitted: March 6, 2018  Accepted: May 19, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2018-001

**Review Article**

**Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy**

Yingying Yang, Yongxian Hu, Jiasheng Wang, He Huang

Zhejiang University School of Medicine First Affiliated Hospital

Blood Cell Therapy Vol.1 Issue.1 No.3 Pages 18-27

Submitted: April 12, 2018  Accepted: July 7, 2018  Published online: August 29, 2018

DOI:https://doi.org/10.31547/bct-2018-003
**Case Report**

**Primary CNS post-transplant lymphoproliferative disorder following haplo-identical HSCT using post-transplant high-dose cyclophosphamide**

Masako Toyosaki, Makoto Onizuka, Jun Amaki, Sawako Shiraiwa, Yasuyuki Aoyama, Shinichiro Machida, Hidetsugu Kawai, Hiromichi Murayama, Daisuke Ogaya, Keiko Matsui, Shohei Kawakami, Kaito Harada, Yusuke Kondo, Kenichi Hirabayashi, Naoya Nakamura, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

1Department of Hematology and Oncology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, 2Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan

Blood Cell Therapy Vol.2 Issue.1 No.1 Pages 1-4

Submitted: May 8, 2018 Accepted: August 9, 2018 Published online: October 26, 2018

DOI:https://doi.org/10.31547/bct-2018-004

**Case Report**

**Successful allogeneic peripheral blood stem cell transplantation for an aggressive variant of T-cell large granular-lymphocyte leukemia: A case report**

Kazuhiro Suzuki, Kaichi Nishiwaki, Jiro Minami, Hidekazu Masuoka, Mitsuji Katori, Hiroki Yokoyama, Hideki Uryu, Shingo Yano

1Division of Clinical Oncology/Hematology, The Jikei University Kashiwa Hospital, 2Division of Clinical Oncology/Hematology, The Jikei University School of Medicine

Blood Cell Therapy Vol.2 Issue.1 No.2 Pages 5-8

Submitted: May 20, 2018 Accepted: September 5, 2018 Published online: October 26, 2018

DOI:https://doi.org/10.31547/bct-2018-006

**Case Report**

**Gastric antral vascular ectasia in a pediatric patient with neuroblastoma who underwent tandem stem cell transplantation**

Yumiko Sugishita, Shohei Yamamoto, Ryota Kaneko, Naoko Okamoto, Masaya Koganesawa, Sachio Fujita, Kosuke Akiyama, Ryosuke Matsuno, Daisuke Toyama, Keiichi Isoyama

Department of Pediatrics, Showa University Fujigaoka Hospital, Japan

Blood Cell Therapy Vol.2 Issue.1 No.3 Pages 9-11

Submitted: August 24, 2018 Accepted: October 2, 2018 Published online: January 15, 2019

DOI:https://doi.org/10.31547/bct-2018-007
Review Article
Autologous hematopoietic stem cell transplant for autoimmune diseases: evolution, evidence of efficacy, and real-world economics
Massey, Jennifer C.1,2,3, Moore, John J.2,3,4, Milliken, Samuel T.4, Ma, David D. F.2,3,4,5
1Department of Neurology, St Vincent’s Hospital Sydney, Australia, 2Blood, Stem Cell and Cancer Research Program, St Vincent’s Centre for Applied Medical Research, Sydney, Australia, 3St Vincent’s Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia, 4Department of Haematology and Bone Marrow Transplant, St Vincent’s Hospital Sydney, Australia, 5Corresponding author
Blood Cell Therapy Vol.2 Issue.2 No.1 Pages 12-21
Submitted: September 14, 2018 Accepted: October 23, 2018 Published online: April 1, 2019
DOI:https://doi.org/10.31547/bct-2018-009

Original Article
Kinetics of neutrophil engraftment in allogeneic stem cell transplantation
Akihisa Kawajiri1, Shigeo Fuji1,2, Yoshihiro Inamoto1, Saiko Kurosawa1, Takashi Tanaka1, Ayumu Ito1, Keiji Okinaka1, Sung-Won Kim1, Takahiro Fukuda1
1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
2Department of Hematology, Osaka International Cancer Institute, Osaka, Japan
Blood Cell Therapy Vol.2 Issue.2 No.2 Pages 22-30
Submitted: October 20, 2018 Accepted: January 23, 2019 Published online: April 1, 2019
DOI:https://doi.org/10.31547/bct-2018-011

Short Communication
A decade of excellent transplant survival in children with inherited metabolic diseases: A report from a single metabolic transplant centre in Europe
Su Han Lum1, Andrew Will1, Heather J Church2, Jean Mercer2, Karen L Tylee2, Kay Poulton2, Wendy Ogdens, Helena Lee2, Alison Logan2, Mary Coussons2, Tasneem Khalids, Denise Bonney1, Stewart Ruts, Prashant Hiwarkar2, Simon A Jones2, Robert F Wynn1
1Department of Pediatric Blood and Marrow Transplant, Royal Manchester Children’s Hospital, UK, 2Manchester Center for Genomic Medicine, St Mary’s Hospital, Manchester, UK, 3Transplantation Laboratory, Manchester Royal Infirmary, Manchester, UK, 4Therapeutic Stem Cell Laboratory, Royal Manchester Children’s Hospital, Manchester, UK, 5Department of Pharmacy, Royal Manchester Children’s Hospital, Manchester, UK, 6Pediatric Psychosocial Department, Royal Manchester Children’s Hospital, Manchester, UK
Blood Cell Therapy Vol.2 Issue.2 No.3 Pages 31-35
Submitted: October 23, 2018 Accepted: February 8, 2019 Published online: May 10, 2019
DOI:https://doi.org/10.31547/bct-2018-012
**Case Report**

*Role of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a report of 2 unique cases*

Yadanar Lwin¹, David Ma¹,²

¹Department of Haematology and BM Transplant, St Vincent’s Hospital Sydney, NSW, Australia, ²St Vincent’s Clinical School, Faculty of Medicine, the University of New South Wales

Blood Cell Therapy Vol.2 Issue.3 No.1 Pages 36-38

Submitted: March 25, 2019  Accepted: April 5, 2019  Published online: June 7, 2019

DOI:https://doi.org/10.31547/bct-2019-001

**Original Article**

*Predictors of parental distress during acute phase of pediatric hematopoietic stem cell transplantation in Japan: A multicenter prospective study*

Shohei Nakajima¹, Ami Setoyama¹, Iori Sato¹, Tomoko Fukuchi², Harumi Tanaka², Masami Inoue³, Kentaro Watanabe³, Katsuyoshi Koh⁴, Junko Takitas⁴, Mika Tokuyama⁴, Kenichiro Watanabe⁴, Kiyoko Kamibeppu¹

¹Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Nursing, Osaka Women’s and Children’s Hospital, Osaka, Japan, ³Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan, ⁴Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan, ⁵Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan, ⁶Department of Hematology and Oncology, Shizuoka Children’s Hospital, Shizuoka, Japan.

Blood Cell Therapy Vol.2 Issue.3 No.2 Pages 39-49

Submitted: October 18, 2018  Accepted: April 15, 2019  Published online: June 18,2019

DOI:https://doi.org/10.31547/bct-2018-010

**Survey Report**

*Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka*

P Abeysinghe¹, L Morawaka², S Gunasekara², S Suresh³, PWDCC Jayathilake¹, PHSP Udara¹, PPR Siriwardena¹, S Milliken², J Moore², DDF Ma³

¹National Cancer Institute, Sri Lanka, ²National Blood Transfusion Service, Sri Lanka, ³Department of Haematology and BM Transplantation, St. Vincent’s Hospital Sydney, NSW, Australia

Blood Cell Therapy Vol.2 Issue.4 No.1 Pages 50-53

Submitted: May 29, 2019  Accepted: August 25, 2019  Published online: November 25, 2019

DOI:https://doi.org/10.31547/bct-2019-007
**Survey Report**

Transplant Programs in APBMT: Blood and Marrow Transplant Activity Report from Myanmar APBMT Meeting 2018, Taiwan

Aye Aye Gyi1, Htun Lwin Nyein2, Thida Aung3, Rai Mra4

1Department of Clinical Haematology, North Okkalapa General and Teaching Hospital, University of Medicine 2, Yangon, Myanmar, 2Department of Clinical Haematology, Yangon General Hospital, Yangon, 3National Blood Center, Yangon, 4Myanmar Society of Haematology, Myanmar Medical Association

Submitted:June 18, 2019  Accepted:September 9, 2019  Published online:November 25, 2019
DOI:https://doi.org/10.31547/bct-2019-008

**Review Article**

Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next-Generation Haematopoietic Stem Cell Transplantation

Sudipto Bari1,3, Paul Chong1, William Ying Khee Hwang1,2,3

1National Cancer Centre Singapore, 2Department of Haematology, Singapore General Hospital, Singapore, 3Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore

Submitted:March 29, 2019  Accepted:September 18, 2019  Published online:November 25, 2019
DOI:https://doi.org/10.31547/bct-2019-004

**Survey Report**

Autologous stem cell transplant program in 2016–country report from Bangladesh

Mafruha Akter1, Mohiuddin Ahmed Khan1, Bimalangshu R Dey2

1BMT Unit, Department of Hematology, Dhaka Medical College Hospital(DMCH), 2Massachusetts General Hospital (MGH), Harvard Medical School, Boston, USA

Blood Cell Therapy Volume 3 (2020) Issue 1 No.1 Pages 1-5
Submitted:May 27, 2019  Accepted:November 18, 2019  Published online:February 25, 2020
DOI:https://doi.org/10.31547/bct-2019-006

**Case Report**

Successful treatment strategy in incorporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report

Keiichi Nakata1, Shigeo Fuji1, Midori Koike1, Yuma Tada1, Hiroaki Masaie1, Hitoshi Yoshida1, Eri Watanabe, Seiichiro Kobayashi, Arinobu Tojo1, Kaoru Uchimaru4, Jun Ishikawa1

1Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, 2Department of IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 3Division of
Original Article

Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation

Minako Iida1, Hideki Nakasone2, Takuya Yamashita3, Masami Inoue4, Yasushi Ishida5, Hitoshi Uchiyama6, Yuta Katayama7, Toshihiro Miyamoto8, Satoshi Yoshioka9, Souichi Shiratori10, Takehiko Mori11, Masashi Sawa12, Yasuhiro Sugio13, Takahiro Fukuda14, Tsuato Ichinohe15, Yoshiro Utsuts16, Yoshihiro Inamoto14, for the Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation

1Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, 2Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 3Department of Hematology, St. Luke's International Hospital, Tokyo, Japan, 4Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan, 5Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Japan, 6Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 7Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 8Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 9Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan, 10Department of Hematology, Hokkaido University Hospital, Sapporo, Japan, 11Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, 12Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan, 13Department of Internal Medicine, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan, 14Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 15Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, 16Japanese Data Center for Hematopoietic Cell Transplantation/Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

Blood Cell Therapy Volume 3 (2020) Issue 1 No.3 Pages 11-17

Submitted: October 18, 2018  Accepted: December 14, 2019  Published online: February 25, 2020

DOI: https://doi.org/10.31547/bct-2019-011

Case Report

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure

Hiroshi Imanaga1, Takanori Ohta2, Seido Oku2, Yasuhiro Sugio3, Yuju Ohno3

1Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan,
Original Article
Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation
Lee YJ1,2, Back DW1,2, Cho HC1,2, Moon JH1,2, Sohn SK1,2
1Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, 2School of Medicine, Kyungpook National University, Daegu, Republic of Korea
Blood Cell Therapy Volume 3 (2020) Issue 2 No.2 Pages 22-31
Submitted:October 2, 2019  Accepted:December 24, 2019  Published online:April 21, 2020
DOI:https://doi.org/10.31547/bct-2019-015

Short Communication
Real-world outcomes of stem cell transplantation for severe aplastic anemia: A single-center experience in Northern India
Dharma Choudhury1, Meet Kumar1, Sanjeev Sharma1, Vipin Khandelwal1, Divya Doval1, Tina Dadu1, Rasika Setia3, Anil Handoo2
1Department of Hematology and BMT, BLK Super Specialty Hospital, New Delhi, 2Department of Hematology, BLK Super Specialty Hospital, New Delhi, 3Department of Transfusion Medicine, Super Specialty Hospital, New Delhi
Blood Cell Therapy Volume 3 (2020) Issue 2 No.3 Pages 32-36
Submitted:December 16, 2019  Accepted:January 31, 2020  Published online:May 25, 2020
DOI:https://doi.org/10.31547/bct-2019-018

Review Article
Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go
James Gajewski
Hebei Yanda Lu Daopei Hospital(consultant), China
Blood Cell Therapy Volume 3 (2020) Issue 3 No.1 Pages 37-43
Submitted:October 4, 2019  Accepted:January 31, 2020  Published online:May 25, 2020
DOI:https://doi.org/10.31547/bct-2019-016

Survey Report
Evolution of Hematopoietic Stem Cell Transplant Programs in Malaysia
Norashikin Saidon1, Nur Adila Anuar2, Chang Kian Meng3, Ong Tee Chuan4, Tan Sen Muis4, Gan Gin Gin2, Fadilah Asia-Pacific Blood and Marrow Transplantation Group
As of July 12, 2022
©2022 APBMT. All rights reserved
Original Article
High Overall and GVHD-Free Survival in Patients with Aplastic Anemia Receiving in vivo T-cell Depletion Transplants and Long-Term Complications
Maria Queralt Salas MD1,2,3, Eshetu G. Atenafu4, Wilson Lam MD1,2, Arjun Datt Law MD1,2, Dennis(Dong Hwan)Kim MD1,2, Fotios V. Michelis MD1,2, Zeyad Al-Shaibani MD1,2, Armin Gerbitz MD1,2, Jeffrey Howard Lipton MD1,2, Auro Viswabandya MD1,2, Jonas Mattsson MD1,2, Vikas Gupta MD1, Rajat Kumar MD1,2
1University of Toronto, Dept of Medicine, Section of Medical Oncology and Hematology, 2Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, 3Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain, 4Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Blood Cell Therapy Volume 3 (2020) Issue 3 No.3 Pages 48-58
Submitted:February 26, 2020  Accepted:May 24, 2020  Published online:July 14, 2020
DOI:https://doi.org/10.31547/bct-2020-001

Guideline
HSCT Guidelines for Transplant Practices During the COVID-19 Pandemic in India [ISBMT DOCUMENT Version1.0]
SharatDamodar1, Vivek S Radhakrishnan2, Joseph John M3, Pankaj Malhotra4, Reetu Jains5, Sameer Melinkeris6, Jose Easow7, Alok Srivastavas, on behalf of the Indian Society for Blood and Marrow Transplantation(ISBMT)
1Mazumdar Shaw Medical Center, Narayana Health City, Bengaluru, 2Tata Medical Center, Kolkata, 3Christian Medical College, Ludhiana, 4Post Graduate Institute of Medical Education and Research, Chandigarh, 5Jaslok Hospital & Research Center, Mumba, 6Deenanath Mangeshkar Hospital and Research Center, Pune, 7Apollo Hospital, Chennai, 8Christian Medical College, Vellore
Blood Cell Therapy Volume 3 (2020) Issue 3 No.4 Pages 59-70
Submitted:May 15, 2020  Accepted:May 26, 2020  Published online:May 28, 2020
DOI:https://doi.org/10.31547/bct-2020-003
**Case Report**

Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases

Wei-Han Huang1,6,7, Chun-Rong Tong2, Tong Wu3, Yun-Chu Lin4, Chi-Cheng Li5,6,7

1Department of Clinical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,
2Department of Hematology, Beijing Boren Hospital, Beijing, China,
3Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China,
4Department of Hematologic Oncology, National Taiwan University Cancer Center, Taipei, Taiwan,
5Department of Hematology & Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,
6Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan,
7School of Medicine, Tzu Chi University, Hualien, Taiwan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.1 Pages 71-73
Submitted:March 29, 2020   Accepted:June 12, 2020   Published online:August 4, 2020
DOI:https://doi.org/10.31547/bct-2020-002

**Case Report**

Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody

Maria Regina Pelobello de Leon1,2, Shuichiro Takahashi1,3, Masahiro Onozawa1, Makoto Itos, Manabu Nakano5, Hajime Senjo1, Masahiro Chiba1, Hiroyuki Ohigashii, Emi Yokoyama1, Junichi Sugita1, Daigo Hashimoto1, Takanori Teshima1

1Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan,
2Department of Medicine, Section of Hematology, Makati Medical Center, Makati City, Phillippines,
3Department of Hematology and Hemotherapy, Sapporo Hokuyu Hospital, Sapporo, Japan,
4Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan,
5Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.2 Pages 74-77
Submitted:May 18, 2020   Accepted:June 26, 2020   Published online:August 31, 2020
DOI:https://doi.org/10.31547/bct-2020-004

**Original Article**

A Novel Hematopoietic Progenitor Cell Mobilization Regimen Comprising Bortezomib, G-CSF, and Preemptive Plerixafor for Multiple Myeloma

Kazuki Tanimoto, Keiji Sakamoto, Ichiro Kawano, Ikumi Yamanaka, Hideho Henzan

Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.3 Pages 78-83
Submitted:May 25, 2020   Accepted:July 29, 2020   Published online:October 9, 2020
DOI:https://doi.org/10.31547/bct-2020-006
**Original Article**

Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies

Takahiko Sato, Naomi Kawashima, Masafumi Ito, Yoshiko Atsuta, Yusuke Kagaya, Aika Seto, Takanobu Morishita, Nobuki Fukushima, Yukiyasu Ozawa, Koichi Miyamura

1Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 2Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 3Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

Blood Cell Therapy Volume 3 (2020) Issue 4 No.4 Pages 84-91

Submitted: June 6, 2020  Accepted: August 9, 2020  Published online: October 16, 2020

DOI: https://doi.org/10.31547/bct-2020-007

**Original Article**

Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia

Christopher Chin Keong Liam, Yang Liang Boo, Yi Lin Lee, Kian Boon Law, Kim Wah Ho, Syed Abdul Kadir Sharifah Shahnaz, Jerome Tsuen Chuen Tan, Ngee Siang Lau, Tee Chuan Ong, Sen Mui Tan, Jameela Sathar

1Department of Haematology, Ampang Hospital, Selangor, Malaysia, 2Centre for Clinical Trial, Ampang Hospital, Selangor, Malaysia

Blood Cell Therapy Volume 4 (2021) Issue 1 No.1 Pages 1-8

Submitted: July 1, 2020  Accepted: September 15, 2020  Published online: December 4, 2020

DOI: https://doi.org/10.31547/bct-2020-009

**Original Article**

Dynamics of Epstein-Barr virus after cord blood transplantation: A nationwide survey in Japan

Akihisa Sawada, Shuichi Taniguchi, Satoshi Takahashi, Masami Inoue, Yasushi Onishi, Masatsugu Tanaka, Hideho Henzans, Masayuki Kubo, Aya Nishida, Keisei Kawa

1Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Izumi, Japan, 2Department of Hematology, Toranomon Hospital, Tokyo, Japan, 3Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 4Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 5Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan, 6Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan, 7Department of Respiratory Medicine, Allergology and Hematology, Nara Medical University Hospital, Kashihara, Japan

Blood Cell Therapy Volume 4 (2021) Issue 1 No.2 Pages 9-14

Submitted: July 8, 2020  Accepted: October 3, 2020  Published online: December 11, 2020  Issued

DOI: https://doi.org/10.31547/bct-2020-010
Case Report
Pharmacokinetics of anti-thymocyte globulin in a patient with severe aplastic anemia treated with allogeneic bone marrow transplantation from a matched unrelated donor

Noriaki Kawano1, Kana Matsumoto2, Akiyoshi Takami3, Taro Tachigi1, Shuro Yoshida1, Takuro Kuriyama1, Takashi Nakaike1, Tomonori Shimokawa1, Koichi Yamashita1, Kyoichi Mashiba1, Ikuo Kikuchi1, Shinji Nakao4
1Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, 2Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts, Kyotanabe, Japan, 3Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Yazakokarimata, Nagakute, Japan, 4Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

Submitted:August 4, 2020  Accepted:October 26, 2020  Published online:December 28, 2020
DOI:https://doi.org/10.31547/bct-2020-012

Original Article
The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region

Minako Iida1, Anthony Dodds2, Mafruha Akter3, Alok Srivastava4, Joon Ho Moon5, Phu Chi Dung6, Marjorie Rose Bravo7, Aya Aya Gyi8, Devinda Jayathilake9, Kaiyan Liu10, Bor-Sheng Ko11, Amir Hamidieh12, Kim Wah Ho13, Aloysius Ho14, Artit Ungkanont15, Tasneem Farzana16, Joycelyn Sim17, Bishesh Poudyal18, Khishigjargal Batshkh19, Shinichiro Okamoto20, Yoshiko Atsuta21, Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group(APBMT)

1Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan, 2St. Vincent’s Pathology, St. Vincent’s Health Network, Sydney, and Australasian Bone Marrow Transplant Recipient Registry(ABMTRR), Sydney, Australia, 3Department of Hematology and BMT, Dhaka Medical College and Hospital, Dhaka, Bangladesh, 4Department of Haematology, Christian Medical College Hospital, Vellore, India, 5Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea, 6Stem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, Vietnam, 7St Luke’s Medical Center Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, Philippines, 8Department of Clinical Haematology, North Okkalapa General Hospital, Yangon, Myanmar, 9Department of Oncology, National Cancer Institute, Maharagama, Sri Lanka, 10Department of Hematology, Peking University Institute of Hematology, Beijing, China, 11Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 12Pediatric Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran, 13Department of Hematology, Hospital Ampang, Ampang Selangor, Malaysia, 14Department of Haematology, Singapore General Hospital, Singapore, 15Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand, 16Department of Clinical Haematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan, 17Department of Medicine, Queen Mary Hospital, Hong Kong, 18Civil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, Nepal,
Original Article

T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center

Dharma Choudhary, Divya Doval, Sanjeev Kumar Sharma, Vipin Khandelwal, Rasika Setia, Anil Handoo

Centre for Bone Marrow Transplant, BLK Superspeciality Hospital, Pusa Road, New Delhi, India

Submitted:September 3, 2020  Accepted:November 13, 2020  Published online:January 29, 2021
DOI:https://doi.org/10.31547/bct-2020-013

Review Article

Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan

Yasuyuki Arai1, Takaaki Konuma2, Masamitsu Yanada3

1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan,
2Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan,
3Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan

Submitted:September 24, 2020  Accepted:November 14, 2020  Published online:January 15, 2021
DOI:https://doi.org/10.31547/bct-2020-014

Case Report

Successful treatment with lenalidomide for relapsed adult T-cell leukemia/lymphoma after cord blood cell transplantation

Katsumichi Fujimaki1, Yuto Hibino1, Kumiko Kishimoto1, Shinichiro Watanabe1, Satoshi Koyama2, Taiki Ando3, Heiwa Kanamori3, Hideaki Nakajima4

1Department of Hematology, Fujisawa City Hospital, Kanagawa, Japan, 2Department of Clinical Laboratory Medicine, Fujisawa City Hospital, Kanagawa, Japan, 3Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa, Japan

Submitted:December 22, 2020  Accepted:February 10, 2021  Published online:April 2, 2021
DOI:https://doi.org/10.31547/bct-2020-023
**Original Article**

**Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation**


1Department of Internal Medicine, 2Radiodiagnosis, 3Endocrinology, Postgraduate Institute of Medical Education and Research

Submitted:November 25, 2020 Accepted:March 2, 2021 Published online:April 30, 2021 Issued DOI:https://doi.org/10.31547/bct-2020-018

**Original Article**

**Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation**

Fan Yang, Yueqian Feng, Changwei Dong, Zhihui Li, Tong Wu

Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China

Submitted:December 1, 2020 Accepted:March 16, 2021 Published online:August 25, 2021 DOI:https://doi.org/10.31547/bct-2020-019

**Original Article**

**Higher Starting Dose of Ciclosporin Optimized Therapeutic Levels in Patients Receiving Phenytoin for Busulfan-induced Seizure Prophylaxis**

Ying Shi Ho, Mui Fong Chong, Vin Cci Ng, Aloysius Ho, Hong Yen Ng

1Department of Pharmacy, Singapore General Hospital, Singapore, 2Department of Hematology, Singapore General Hospital, Singapore

Submitted:December 31, 2020 Accepted:March 20, 2021 Published online:August 25, 2021 DOI:https://doi.org/10.31547/bct-2020-025

**Original Article**

**Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation in an Asian Patient Population**

Chong Mui Fong, Lim Yan Jiun, Ng Hong Yen
State of the Art
Toxicity of Chimeric Antigen Receptor T Cells and its Management
Kitsada Wudhikarn1, Shui Yen Soh2, He Huang3, Miguel-Angel Perales4,5
1Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 2Paediatric Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore, 3The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 4Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA, 5Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Submitted:August 7, 2021 Accept:August 15, 2021 Published online:October 14, 2021 Issued DOI:https://doi.org/10.31547/bct-2021-011

State of the Art
Highlights of Pharmacist Roles in Hematopoietic Cell Transplantation and Cellular Therapy
Ho Ying Shi1, Trai Tharnpanich2, Bo Yu3
1Department of Pharmacy, Singapore General Hospital, Singapore, 2Faculty of Pharmaceutical Sciences Chulalongkorn University, Bangkok, Thailand, 3Department of Pharmacy, and Clinical Research Institute Office, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Submitted:August 20, 2021 Accepted:August 20, 2021 Published online:October 14, 2021 DOI:https://doi.org/10.31547/bct-2021-016

State of the Art
Standardization and Accreditation in Haemopoietic Stem Cell Transplantation – an Asia Pacific Perspective
Sharat Damodar1, David D Ma2,3, Scott J Ragg4, Annabella Changs, William YK Hwang5, Aloysius YL Ho6, Alok Srivastava7
1Dept of Haematology and BMT, Mazumdar shaw medical center, Narayana health city, India, 2Department of Haematology and BM Transplant, St Vincent's Hospital Sydney, NSW, Australia, 3St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia, 4Royal Hobart Hospital, Hobart. TAS. Australia, 5St Vincent's Centre for Applied Medical Research, Sydney NSW Australia, 6Department of Haematology, Singapore General Hospital, Singapore, 7Dept of Haematology, CMC Vellore, India
State of the Art
Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
Hee-Je Kim1, Daniel Weisdorf2, David J Gottlieb3
1Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, the Republic of Korea, 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, U.S.A, 3Westmead Hospital University of Sydney, Sydney, Australia
Submitted:August 16, 2021  Accepted:September 1, 2021  Published online:October 14, 2021
DOI:https://doi.org/10.31547/bct-2021-014

Original Article
Haploidentical Hematopoietic Stem Cell Transplant Using Post- transplant Cyclophosphamide: A Single-Center Initial Experience in Vietnam
Man Van Huynh, Quang The Nguyen, Phu Duc Vinh Huynh, Nam Duy Hoang, Thu Hanh Nguyen, Dung Chi Phu
Stem Cell Transplantation Department, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam
Blood Cell Therapy Volume 4 (2021) Issue 4 No.1 Pages 75-83
Submitted:April 1, 2021  Accepted:May 30, 2021  Published online:November 25, 2021  Issued
DOI:https://doi.org/10.31547/bct-2021-002

Short Communication
Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020
Rizwan Javed1, Mita Roychowdhury2, Saurabh Bhave3, Arijit Nag3, Jeevan Kumar3, Vivek Radhakrishnan3, Sanjay Bhattacharyas3, Deepak Kumar Mishras3, Niharendu Gharsas3, Reena Nair3, Mammen Chandy3
1Apheresis & Cell processing unit, Department of Clinical Haematology and BMT, TATA Medical Center, Kolkata, 2TATA Medical Center, Kolkata, 3Department of Clinical Haematology and BMT, TATA Medical Center, Kolkata, 4Microbiology, TATA Medical Center, Kolkata, 5Laboratory Haematology, TATA Medical Center, Kolkata, 6Department of Paediatric Haematology and Oncology, TATA Medical Center, Kolkata
Submitted:May 27, 2021  Accepted:July 16, 2021  Published online:November 25, 2021  Issued
DOI:https://doi.org/10.31547/bct-2021-004
Case Report
Severe graft-versus-host disease of the lower intestinal tract after pomalidomide administration in a plasma cell leukemia patient following bone marrow transplantation
Hiroto Ishii, Hiroki Yokoyama, Atsushi Katsube, Tadahiro Gunji, Takeshi Saito, Shingo Yano
Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
Submitted:June 6, 2021  Accepted:August 3, 2021  Published online:November 25, 2021  Issued
DOI:https://doi.org/10.31547/bct-2021-006

Original Article
HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA – ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA
Lawrence Cheng Kiat Ng1, Christopher Shwei Wen Tham1, Francesca Wei Inng Lim1, Yunxin Chen1, Shin Yeu Ong1, Chandramouli Nagarajan1, Jing Jing Lee1, Yeow Tee Goh1, Yeh Ching Linn1, Yuh Shan Lee1,2, Colin Diong Phipps1,2, Jeffrey Kim Siang Quek1, Than Hein1, Jordan Chung Cheng Hwang1, Nicholas Grigoropoulos1, William Ying Khee Hwang1, Aloysius Yew Leng Ho1
1Department of Haematology, Singapore General Hospital, Singapore, 2Parkway Cancer Centre, Singapore
Blood Cell Therapy Volume 4 (2021) Issue 4 No.4 Pages 92-100
Submitted:June 8, 2021  Accepted:August 7, 2021  Published online:November 25, 2021  Issued
DOI:https://doi.org/10.31547/bct-2021-007

State of the Art
Novel Treatment for Graft-versus-Host Disease
Yoshihiro Inamoto1, Robert Zeiser2, Godfrey Chi-Fung Chan3,4,5
1Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 2Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University (ALU), Freiburg, Germany, 3Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, 4Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, 5Department of Paediatrics and Adolescent Medicine, HKU-Shenzhen Hospital
Submitted:October 1, 2021  Accepted:October 16, 2021  Published online:November 25, 2021
DOI:https://doi.org/10.31547/bct-2021-022
Appendix
## Cooperate Members

<table>
<thead>
<tr>
<th>Annual sponsorship</th>
<th>Center for Supporting Hematology-Oncology Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Astellas</td>
</tr>
<tr>
<td></td>
<td>AIR WATER</td>
</tr>
<tr>
<td>Banner Contributions</td>
<td>MSD</td>
</tr>
<tr>
<td>International sponsorship for the APBMT 2021 Thailand</td>
<td>Kite Pharma</td>
</tr>
<tr>
<td></td>
<td>Terumo Thailand</td>
</tr>
<tr>
<td></td>
<td>Miltenyi</td>
</tr>
</tbody>
</table>
APBMT Annual Report 2021

APBMT officers

President
Shinichiro Okamoto
Department of Medicine
Keio University School of Medicine
35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan
Tel: +81 3 3335 1221
okamoto.a7@keio.jp

Secretariat office
E-mail: office@apbmt.org
Website: http://www.apbmt.org
Department of Promotion for Blood and Marrow Transplantation
Aichi Medical University School of Medicine
1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan
Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180

Minako Iida
miida@aichi-med-u.ac.jp

Yukari Nakao
yukari-nakao@aichi-med-u.ac.jp

Hiroe Namizaki
namizaki@aichi-med-u.ac.jp